Phathom Pharmaceuticals, Inc. PHAT
7.30
0.31
4.43%
as of 25 Sep
- Market cap
- $572.8M
- P/E
- 0.0×
Follow PHAT
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 26.42% | 46.58% | 63.97% | 90.07% |
+8 more TTM periods Free account |
|
| (34.32%) | (52.49%) | (69.41%) | (87.53%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(69.23%) | (103.12%) | (225.78%) | (237.06%) | |
Average Days of Receivables |
148.37 | 143.80 | 162.85 | 138.34 | |
Free Cash Flow per Share |
(0.44) | (1.19) | (2.29) | (3.07) | |
Free Cash Flow |
(36.91) | (97.76) | (167.00) | (225.38) | |
Capital Expenditures |
(0.22) | (0.27) | (0.23) | (0.15) | |
Piotroski F-Score |
4.00 | 4.00 | 4.00 | 4.00 | |
| Other line items | |||||
Cash ROIC |
(1,314.22%) | (1,278.75%) | 168.27% | 280.54% | |
Accounts Receivable Turnover |
3.22 | 3.50 | 3.00 | 3.83 | |
Accounts Payable Turnover |
8.74 | 3.43 | 2.92 | 4.57 | |
Inventory Turnover |
7.35 | 6.38 | 5.18 | 5.58 | |
Average Days of Payables |
47.81 | 75.26 | 80.48 | 20.91 | |
Days of Inventory on Hand |
68.78 | 76.95 | 89.12 | 70.23 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
12.56% | 15.31% | 18.72% | 23.01% | |
Selling, General and Administrative Expense of Revenue |
87.32% | 116.77% | 159.74% | 209.27% | |
Share Based Compensation of Revenue |
11.33% | 14.01% | 16.40% | 20.24% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.37 | 0.62 | 0.75 | 0.82 | |
Depreciation/Fixed assets |
3.96 | 3.67 | 3.43 | 3.06 | |
Capex/Depreciation |
(0.06) | (0.07) | (0.06) | (0.04) | |
Revenue per Share |
2.86 | 2.50 | 2.40 | 2.01 | |
Operating CF per Share |
(0.44) | (1.19) | (2.29) | (3.07) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
(41.34%) | (76.77%) | (126.35%) | (186.53%) |
Columns are period end dates